3D InSight™ | 3D In Vitro Immuno-Oncology Screening
Our 3D InSight™ Immuno-Oncology Platform provides you with an end-to-end solution to interrogate mechanisms of action to efficacy and safety of IO agents
3D In Vitro Immuno-Oncology Screening
Have you experienced any of the typical challenges in preclinical models for Immuno-Oncology screening?
- The accurate modeling of the tumor microenvironment
- The lack of longitudinal follow-up of the complex tumor-immune cell interactions
- The inability to accurately model the effect of physiological flow on the infiltration of immune cells and the consequent effect on tumor growth
- Immune cell isolation and culture
3D InSight™ Immuno-Oncology Platform
- Over 15 years of experience with 3D in vitro technology. Robust, Reproducible, and Physiologically relevant human models enable endpoints for any therapeutic candidate with much faster turnaround times compared to 2D culture.
- Scalable, and predictive in vitro 3D human models bridging the gap between in vitro and in vivo translation. 30 tumor cell lines from 11 different tissues co-cultured with stromal and/or immune cells in addition to 3D PDX models.
- 3D InSight™ Human Tumor Microtissues - first-in-class in vitro model enabling
ADC Penetration Depth assessment. Our highly scalable and predictive 3D cell culture cancer spheroids reflect the physiology of the tumor, enabling accurate and simultaneous assessment of ADC’s efficacy and penetration depth.
Why Immuno-Oncology Screening with InSphero?
Our 3D InSight™ Immuno-Oncology Screening platform models immune-tumor cell interaction to answer your specific biological questions, allocating your valuable resources most effectively.
Measure changes in the tumor microenvironment
Using multiplexed readouts, determine the phenotypic differences among various cell types in the tumor microenvironment
Antibody penetration with 3D human tumor microtissues
For antibody-mediated therapies, explore the tissue equivalent penetration of your antibody in our reliable 3D InSight ™ oncology microtissues
Tumor-specific cell killing or escape
Accurately assess the contribution of the immune system to tumor growth or death in our physiologically relevant tumor microtissues
Our Process in Immuno-Oncology Screening
Context of use
Identify the biological question that needs to be asked and build an immuno-oncology relevant model ensuring a tailor-made solution
Fast, convenient turnaround times
Multiplex endpoints for informative solutions
